DSUVIA Drug Insight and Market Forecast - 2032

"DSUVIA Drug Insight and Market Forecast - 2032" report provides comprehensive insights about DSUVIA for acute pain in the United States. A detailed picture of the DSUVIA for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the DSUVIA for acute pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DSUVIA market forecast analysis for acute pain in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in acute pain.

Drug Summary:

DSUVIA (sufentanil) is an opioid agonist that contains sufentanil and is indicated for use in adults in certified medically supervised healthcare settings, such as hospitals, surgical centers, and emergency departments, for managing acute pain. DSUVIA is administered in the form of a tablet sublingually to the patient. However, the intensity of pain must be severe enough to require an opioid analgesic and for which alternative treatments are inadequate. In January 2021, AcelRx announced an investigator-initiated study with University Hospitals Cleveland Medical Center to evaluate the postoperative use of the drug in a prospective cohort of patients undergoing cardiac surgery with cardiopulmonary bypass following a specialized enhanced recovery protocol. In August 2020, an investigator-initiated study with Cleveland Clinic was initiated to assess the effects of DSUVIA on postoperative recovery from orthopedic surgery.

Dosage and administration

The recommended dosage of DSUVIA is 30 mcg sublingually as needed, with a minimum of 1 h between doses; do not exceed 12 tablets in 24 h. The maximum cumulative dose is 360 mcg or 12 tablets (12 tablets × 30 mcg/dose).

Mechanism of action

Sufentanil is an opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of sufentanil is analgesia and sedation, thought to be mediated through opioid-specific receptors throughout the CNS; like all full opioid agonists, there is no ceiling effect to analgesia.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the DSUVIA description, mechanism of action, dosage and administration, research and development activities in acute pain.
• Elaborated details on DSUVIA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DSUVIA research and development activities in acute pain across the United States.
• The report also covers the patents information with expiry timeline around DSUVIA.
• The report contains forecasted sales of DSUVIA for acute pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for acute pain.
• The report also features the SWOT analysis with analyst views for DSUVIA in acute pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DSUVIA Analytical Perspective by DelveInsight

In-depth DSUVIA Market Assessment

This report provides a detailed market assessment of DSUVIA for acute pain in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

DSUVIA Clinical Assessment

The report provides the clinical trials information of DSUVIA for acute pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for acute pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DSUVIA dominance.
• Other emerging products for acute pain are expected to give tough market competition to DSUVIA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DSUVIA in acute pain.
• Our in-depth analysis of the forecasted sales data of DSUVIA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DSUVIA in acute pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of DSUVIA?
• What is the clinical trial status of the study related to DSUVIA in acute pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DSUVIA development?
• What are the key designations that have been granted to DSUVIA for acute pain?
• What is the forecasted market scenario of DSUVIA for acute pain?
• What are the forecasted sales of DSUVIA in the United States?
• What are the other emerging products available and how are these giving competition to DSUVIA for acute pain?
• Which are the late-stage emerging therapies under development for the treatment of acute pain?